Drug intelligence / Profile preview

rabies vaccine (Vero cells) (Sanofi)

Development stage
Unknown
Lead developer
Sichuan Center for Disease Control
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

Rabies vaccine (Vero cells) is an inactivated viral vaccine produced by propagating rabies virus strains, such as the Pitman-Moore (PM) strain, in Vero cell cultures (a continuous lineage of kidney epithelial cells from the African green monkey). This technology allows for large-scale production of high-purity vaccines compared to older nerve-tissue or primary cell culture methods. The vaccine is typically inactivated using beta-propiolactone and then purified and lyophilized to ensure stability. It is used for both pre-exposure prophylaxis (PrEP) in high-risk individuals and post-exposure prophylaxis (PEP) following potential rabies exposure. The vaccine is highly immunogenic, inducing protective levels of neutralizing antibodies against the rabies virus G protein. It is widely used globally and is a cornerstone of rabies prevention programs in China and other endemic regions.

Brand names
VerorabAbhayrabSpeedaIndirab
Other names
Purified Vero Cell Rabies VaccineHuman Rabies Vaccine (Vero Cell)lyophilized human rabies vaccine (Vero cells)
02

Targets

Rabies virus nucleoprotein (N protein)RABV-G (Rabies virus glycoprotein)

Beyond the preview

Go deeper on rabies vaccine (Vero cells) (Sanofi).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on rabies vaccine (Vero cells) (Sanofi).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call